title: Targeting BCR-ABL and JAK2 in Ph+ ALL.
abstract: In this issue of Blood, Appelmann et al provide evidence for prolonged survival and prevention of resistance in a mouse model of Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) by combined targeting of the BCR-ABL kinase and Janus kinase 2 (JAK2) with dasatinib and ruxolitinib, respectively.
authors.affiliation: SWISS INSTITUTE FOR EXPERIMENTAL CANCER RESEARCH (ISREC).
authors.forename: Oliver
authors.initials: O
authors.lastname: Hantschel
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
chemical_list: D053612:Janus Kinases